Loading
Giving 65 patients with advanced pancreatic cancer a PD-L1 antibody alone or with a CTLA-4 antibody shrank tumours in 3% and 0%, so the trial was stopped before its second stage.
Part A of a two-part phase 2 randomised trial was a lead-in safety, open-label study with planned expansion pending an efficacy signal. Between November 2015 and March 2017, 65 patients with metastatic pancreatic ductal adenocarcinoma who had received one prior fluorouracil- or gemcitabine-based line were enrolled at 21 sites in 6 countries and randomised to durvalumab 1500 mg every 4 weeks plus tremelimumab 75 mg every 4 weeks for 4 cycles then durvalumab, or durvalumab monotherapy. Grade 3 or higher treatment-related adverse events occurred in 22% and 6%. Objective response rate was 3.1% for combination and 0% for monotherapy; the 10% threshold for expansion was not met and part B did not open. Patient numbers limited any association with PD-L1 expression or microsatellite instability.
Dual checkpoint blockade, which rescued other cold tumours, does not work in unselected pancreatic cancer; combinations must change the microenvironment first.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Metastatic pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Metastatic pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, Pancreatic ductal adenocarcinoma.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1.
Shares Eileen M. O'Reilly, Pancreatic ductal adenocarcinoma.